Coupang Inc vs Nuwellis Inc — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Coupang Inc is far larger — about 12590.9× Nuwellis Inc's market cap, and Coupang Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Nuwellis Inc for 26 Days on average.
| CPNG | NUWE | |
|---|---|---|
Market Cap | $27.70B | $2.20M |
Volume | 27,703,608 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.13 | $146.65 |
52-Week Low | $13.75 | $0.68 |
Typical Hold Time | 55 Days | 26 Days |
Enterprise Value | $27.22B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.41, up 4.05% today, with a bullish technical signal and strong analyst support. Revenue grew to $34.53B in 2025, though recent quarterly EPS misses and a negative net income margin of -2.16% highlight profitability challenges. The stock is supported by positive cash flow from operations of $1.77B and a dominant e-commerce position in South Korea, but faces competitive pressure and a projected net loss in 2026.
The outlook balances high growth potential against near-term earnings volatility. Investment appeal lies in market dominance and analyst consensus price target of $25.25, implying significant upside, but risks include intense competition, regulatory scrutiny from U.S.-South Korea trade tensions (CNBC, 2026-08-31), and execution hurdles in expanding logistics networks.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →